Italia markets closed

Dow Jones
39.839,72
+32,95(+0,08%)
Nasdaq
16.799,85
+4,97(+0,03%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0858
-0,0004(-0,03%)
Bitcoin EUR
64.108,63
+1.075,60(+1,71%)
CMC Crypto 200
1.516,03
+27,49(+1,85%)

NVCR May 2024 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

4,5200

-0,1800

(-3,83%)

In data: 03:59PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in